Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 13, 2023Frontiers in ImmunologyOpen Access

Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

TZTobias ZellerLudwig-Maximilians-Universität MünchenIMIra A. MünnichLudwig-Maximilians-Universität MünchenRWRoland WindischBoston Children's Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zeller et al. (2023) studied this question.

synapsesocial.com/papers/6a00627fe4618ba4162daa07https://doi.org/10.3389/fimmu.2023.1240275
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Overexpression of CD85j in TNBC patients inhibits Cetuximab‐mediated NK‐cell ADCC but can be restored with CD85j functional blockade2015 · 51 citations
  2. 2Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?2021 · 113 citations
  3. 3Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia2018 · 47 citations
  4. 4Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT22003 · 54 citations